Adding TRT and hormone therapy to a GLP-1 brand
Your GLP-1 patients are asking about testosterone and menopause care, and the audience overlap is real. The operations overlap less than it looks: hormones bring labs, monitoring, and — for TRT — controlled-substance rules your weight-care flow never had to handle.
Lithos Staff
Photograph via UnsplashHormone therapy is a natural second vertical for a GLP-1 brand, but it runs on a different clinical pattern: baseline and follow-up labs are mandatory, testosterone is a Schedule III controlled substance requiring a synchronous visit and EPCS under current telemedicine rules, and monitoring is on a quarterly lab cadence rather than a monthly dose step. The way to add it without splitting your funnel is one intake front door with product-aware branching, a shared patient record, and a rules layer that routes hormone cases into the lab-first, synchronous-where-required path automatically. Launch HRT (largely non-controlled) before TRT if you want the easier first step.
Same audience, different machine
A GLP-1 program is built around a monthly dose step, an async check-in, and a compounded injectable. A hormone program is built around labs: a baseline panel before the first prescription, follow-up panels on a schedule, and dose decisions driven by results rather than a calendar. For testosterone, add the controlled-substance layer. The audience overlap makes the expansion attractive; the operational differences are what make it a project rather than a checkbox.
What changes, side by side
| GLP-1 weight care | HRT (estrogen / progesterone) | TRT (testosterone) | |
|---|---|---|---|
| Controlled substance | No | Generally no | Yes — Schedule III |
| Visit modality | Async where state allows | Async in many states | Synchronous under current federal telemedicine rules |
| Labs before first Rx | Protocol-dependent; often baseline metabolic panel | Protocol-dependent | Required — testosterone levels plus safety markers |
| Monitoring cadence | Monthly check-in with dose step | Symptom check-ins; labs periodically | Labs at intervals; hematocrit and other safety monitoring |
| Prescribing | eRx | eRx | EPCS with identity-proofed prescriber |
| Pharmacy | Compounding bench | Compounding or retail | Pharmacy with controlled-substance registration in the state |
| State variation | Modality rules | Modality rules | Modality rules plus state controlled-substance telehealth rules |
One funnel, product-aware branching
The mistake is to launch hormones as a separate site with a separate intake and, eventually, a separate patient record. The patient who started on GLP-1s and now wants TRT is your best lead; make them start over and you lose the history, the trust, and often the patient. The structure that works:
- One front door. Shared identity, history, medications, and goals. The patient picks a program or the intake infers it.
- Product-aware branching. The hormone branch adds symptom inventories, lab history, and the screens that decide whether a synchronous visit is required.
- A rules layer that routes. State plus product plus answers determines async vs. live visit, which labs to order first, and which pharmacy can fill. See asynchronous telehealth.
- One record. The GLP-1 clinician note, the hormone labs, and both prescriptions live on the same patient. Interactions get checked; the patient sees one care team.
- One subscription surface. A second line item on the existing membership, not a second checkout.
The lab workflow is the real build
Hormone programs live and die on labs: ordering the right panel, getting the patient to a draw site or shipping an at-home kit, ingesting results, getting a clinician to act on them, and repeating on schedule. Programs that treat labs as a manual step drown in support tickets by month two. Labs need to be an event in the same pipeline as visits and prescriptions: ordered from the encounter, results attached to the record, clinician review triggered automatically, and the next draw scheduled from the protocol. See how to offer hormone therapy online.
Sequencing the expansion
- Start with HRT if you want the easier step: non-controlled, async-friendly, lab-driven. It proves the lab workflow.
- Add TRT once labs are routine: it needs synchronous visits, EPCS, and controlled-substance pharmacy routing, and current telemedicine rules for controlled substances should be re-checked at launch. See the 2026 DEA map.
- Cross-sell from the check-in. The monthly GLP-1 check-in is the natural moment to screen for hormone symptoms and offer the second program to eligible patients — with a clinician, not a banner, making the call.
Frequently asked questions
Can testosterone be prescribed via telehealth?
Yes, within federal and state controlled-substance rules. Testosterone is Schedule III, so under the current telemedicine framework the prescribing encounter generally needs to be a real-time audio-video visit, prescribed electronically with EPCS, with labs supporting the diagnosis. State rules can add requirements.
What labs are needed before starting TRT or HRT?
Protocols vary by clinician and program, but TRT typically requires at least a baseline total testosterone (often repeated), plus hematocrit and other markers, with follow-up labs at intervals. HRT protocols vary more; some regimens can start on history and symptoms with labs used for monitoring. The medical group’s protocol governs.
Can we use the same intake for GLP-1 and hormones?
One front door, yes — with branching. The first screens are shared (identity, history, medications, goals); the hormone branch adds symptom inventories, lab history, and the questions that determine whether a synchronous visit is required. Do not bolt a second questionnaire onto the end of the first.
Should we launch TRT or HRT first?
HRT is usually the easier operational step because most regimens are not controlled substances and can run async where state rules allow. TRT adds the synchronous visit, EPCS, and controlled-substance pharmacy routing. Many brands launch HRT first and add TRT once the lab workflow is proven.
From first call to first patient, in weeks.
A 15-minute intro call, sandbox credentials the same day, go-live in 3–4 weeks — new launches and existing patient bases alike.